The litigation centers on allegations that the company issued materially misleading statements regarding its business operations and trading activity. According to the complaint, Park Ha was the target of a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals to artificially inflate share prices. The suit further claims the company’s IPO was intentionally structured with a restricted public float to facilitate this manipulation, while failing to disclose these risks to the public.
Investors Face September Deadline in Park Ha Securities Fraud Suit
Investors who purchased Park Ha Biological Technology Co., Ltd. securities between December 27, 2024, and July 8, 2025, have until September 28, 2026, to file as lead plaintiffs in a pending class action lawsuit, the Rosen Law Firm announced today.

Investors are not required to take immediate action to remain part of the potential class, though those wishing to serve as lead plaintiff must move the court by the late September deadline. Rosen Law Firm, which is handling the case, notes that no class has been certified yet. Shareholders may select their own counsel or choose to remain absent members of the class. The firm encourages those interested in participating to contact Phillip Kim for further details regarding the contingency fee arrangement.


Comments (0)
No comments yet. Be the first!